CD40 | Immune checkpoint catalytic receptors | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

CD40

  Target has curated data in GtoImmuPdb

Target id: 1874

Nomenclature: CD40

Systematic Nomenclature: TNFRSF5

Family: Immune checkpoint catalytic receptors, Tumour necrosis factor (TNF) receptor family

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 277 20q13.12 CD40 CD40 molecule
Mouse 1 289 Cd40 CD40 antigen
Rat - - Cd40 CD40 molecule
Previous and Unofficial Names
CD40 molecule, TNF receptor superfamily member 5 | TNFRSF5
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
UniProtKB
Wikipedia
Natural/Endogenous Ligands
CD40 ligand {Sp: Human}
Adaptor proteins (Human)
TRAF1, TRAF2, TRAF3, TRAF5, TRAF6

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
CFZ533 Hs Binding 9.2 pKd 1
pKd 9.2 (Kd 6.9x10-10 M) [1]
Description: Measured using a Biacore assay.
Antibody Comments
Other anti-CD40 mAbs in clinical development include ABBV-323 (ravagalimab; for Crohn's disease) and JNJ-64457107 (vanalimab, ADC-1013; a CD40 agonistic mAb in Phase 1 immuno-oncology trial NCT02829099)
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
CD40 ligand {Sp: Human} Hs - - -
Immunopharmacology Comments
CD40 is a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). It is expressed on a variety of immune cells, including macrophages, B cells, and dendritic cells (DCs). CD40 plays a key role in the activation of the immune system. Endogenous ligand is CD154 (CD40L) on TH cells. CD40 is an immunotherapy and immuno-oncology clinical target. Anti-CD40 agonistic monoclonal antibodies that induce activation and proliferation of effector and memory T cells, and enhance the immune response against tumour cells, are in clinical development.
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 3 GO processes
GO:0006954 inflammatory response TAS
click arrow to show/hide IEA associations
GO:0034341 response to interferon-gamma IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 4 GO processes
GO:0042100 B cell proliferation NAS
click arrow to show/hide IEA associations
GO:0030890 positive regulation of B cell proliferation IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
GO:0051023 regulation of immunoglobulin secretion IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 5 GO processes
GO:0050776 regulation of immune response TAS
click arrow to show/hide IEA associations
GO:0002768 immune response-regulating cell surface receptor signaling pathway IEA
GO:0030890 positive regulation of B cell proliferation IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
GO:0051023 regulation of immunoglobulin secretion IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 5 GO processes
GO:0033209 tumor necrosis factor-mediated signaling pathway TAS
click arrow to show/hide IEA associations
GO:0032735 positive regulation of interleukin-12 production IEA
GO:0034341 response to interferon-gamma IEA
GO:0036018 cellular response to erythropoietin IEA
GO:0071347 cellular response to interleukin-1 IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 4 GO processes
GO:0042100 B cell proliferation NAS
click arrow to show/hide IEA associations
GO:0002768 immune response-regulating cell surface receptor signaling pathway IEA
GO:0030890 positive regulation of B cell proliferation IEA
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0048304 positive regulation of isotype switching to IgG isotypes IEA

References

Show »

1. Heusser C, Rush J, Vincent K. (2012) Silent fc variants of anti-cd40 antibodies. Patent number: WO2012065950. Assignee: Novartis Ag. Priority date: 15/11/2010. Publication date: 24/05/2012.

How to cite this page

Select citation format: